SEC Form 4 · accession 0001836297-26-000005
BioAge Labs, Inc. · BIOA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shane Barton
Officer — Principal Accounting Officer
Period of report
Jun 29, 2026
Accepted (ET)
Jul 1, 2026 · 4:27 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001709941
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2026 | M | 9,301 | $10.85 | A | 11,933 | D | |
| Common Stock | Jun 29, 2026 | M | 7,261 | $8.39 | A | 19,194 | D | |
| Common Stock | Jun 29, 2026 | M | 8,958 | $4.30 | A | 28,152 | D | |
| Common Stock | Jun 29, 2026 | M | 14,198 | $4.38 | A | 42,350 | D | |
| Common StockF2 | Jun 29, 2026 | S | 42,350 | $25.2084 | D | 0 | D | |
| Common Stock | Jun 30, 2026 | M | 4,290 | $10.85 | A | 4,290 | D | |
| Common Stock | Jun 30, 2026 | M | 4,000 | $8.39 | A | 8,290 | D | |
| Common Stock | Jun 30, 2026 | M | 4,065 | $4.30 | A | 12,355 | D | |
| Common Stock | Jun 30, 2026 | M | 7,861 | $4.38 | A | 20,216 | D | |
| Common StockF3 | Jun 30, 2026 | S | 20,216 | $25.1868 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $10.85 | Jun 29, 2026 | M | 9,301 | D | — | Sep 26, 2033 | Common Stock | 9,301 | 17,589 | D |
| Stock Option (Right to Buy)F5 | $8.39 | Jun 29, 2026 | M | 7,261 | D | — | Apr 16, 2034 | Common Stock | 7,261 | 21,016 | D |
| Stock Option (Right to Buy)F6 | $4.30 | Jun 29, 2026 | M | 8,958 | D | — | Dec 17, 2034 | Common Stock | 8,958 | 31,042 | D |
| Stock Option (Right to Buy)F7 | $4.38 | Jun 29, 2026 | M | 14,198 | D | — | Feb 17, 2035 | Common Stock | 14,198 | 75,802 | D |
| Stock Option (Right to Buy)F4 | $10.85 | Jun 30, 2026 | M | 4,290 | D | — | Sep 26, 2033 | Common Stock | 4,290 | 13,299 | D |
| Stock Option (Right to Buy)F5 | $8.39 | Jun 30, 2026 | M | 4,000 | D | — | Apr 16, 2034 | Common Stock | 4,000 | 17,016 | D |
| Stock Option (Right to Buy)F6 | $4.30 | Jun 30, 2026 | M | 4,065 | D | — | Dec 17, 2034 | Common Stock | 4,065 | 26,977 | D |
| Stock Option (Right to Buy)F7 | $4.38 | Jun 30, 2026 | M | 7,861 | D | — | Feb 17, 2035 | Common Stock | 7,861 | 67,941 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive.
- F4The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
- F5The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
- F6The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
- F7The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.